The place of excision repair cross complementation 1 (ERCC1) in surgically treated non-small cell lung cancer

European Journal of Cardio-thoracic Surgery

Volumn 33, Issue 5, 2008, Pages 805-811

  Breen, David ^a,b   Barlési, Fabrice ^a  

^a HÔPITAL SAINTE MARGUERITE   (France)

^b ST JAMES S HOSPITAL   (Ireland)

Author keywords

Adjuvant chemotherapy; ERCC1; Non small cell lung cancer; Prognostic; Thoracic surgery

Indexed keywords

ANTINEOPLASTIC AGENT; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; PLATINUM DERIVATIVE;

CANCER ADJUVANT THERAPY; CANCER SURGERY; CANCER SURVIVAL; DIAGNOSTIC VALUE; DNA ADDUCT; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; HUMANS; LUNG NEOPLASMS; PLATINUM; PREDICTIVE VALUE OF TESTS; SURVIVAL RATE;

EID: 41949102163     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2008.01.067     Document Type: Review

References (42)

1. Bepler G., Gautam A., McIntyre L.M., Beck A.F., Chervinsky D.S., Kim Y.C., Pitterle D.M., and Hyland A. Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer. J Clin Oncol 20 (2002) 1353-1360
2. Doddoli C., Barlesi F., Trousse D., Robitail S., Yena S., Astoul P., Giudicelli R., Fuentes P., and Thomas P. One hundred consecutive pneumonectomies after induction therapy for non-small cell lung cancer: an uncertain balance between risks and benefits. J Thorac Cardiovasc Surg 130 (2005) 416-425
3. Romano P.S., and Mark D.H. Patient and hospital characteristics related to in-hospital mortality after lung cancer resection. Chest 101 (1992) 1332-1337
4. Alberts WM. American College of Chest Physicians. Introduction: Diagnosis and management of lung cancer: ACCP evidence-based clinical practice guidelines. Chest 123 1 suppl (2003) 1S-337S
5. Molina J.R., Adjei A.A., and Jett J.R. Advances in chemotherapy of non-small cell lung cancer. Chest 130 (2006) 1211-1219
6. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997;15:2996-3018.
7. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
8. Hirsch F.R., and Witta S. Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer. Curr Opin Oncol 17 (2005) 118-122
9. Friedberg E.C. How nucleotide excision repair protects against cancer. Nat Rev Cancer 1 (2001) 22-33
10. Altaha R., Liang X., Yu J.J., and Reed E. Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med 14 (2004) 959-970
11. Jordan P., and Carmo-Fonseca M. Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci 57 (2000) 1229-1235
12. Bosken C.H., Wei Q., Amos C.I., and Spitz M.R. An analysis of DNA repair as a determinant of survival in patients with non-small cell lung cancer. J Natl Cancer Inst 94 (2002) 1091-1099
13. Zhou W., Liu G., Park S., Wang Z., Wain J.C., Lynch T.J., Su L., and Christiani D.C. Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer. Cancer Epidemiol Biomarkers Prev 14 (2005) 491-496
14. Simon G.R., Sharma S., Cantor A., Smith P., and Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 127 (2005) 978-983
15. Langer R., Specht K., Becker K., Ewald P., Bekesch M., Sarbia M., Busch R., Feith M., Stein H.J., Siewert J.R., and Hofler H. Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma. Clin Cancer Res 11 (2005) 7462-7469
16. Li Q., Yu J.J., Mu C., Yunmbam M.K., Slavsky D., Cross C.L., Bostick-Bruton F., and Reed E. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res 20 (2000) 645-652
17. Metzger R., Leichman C.G., Danenberg K.D., Danenberg P.V., Lenz H.J., Hayashi K., Groshen S., Salonga D., Cohen H., Laine L., Crookes P., Silberman H., Baranda J., Konda B., and Leichman L. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16 (1998) 309-316
18. Shirota Y., Stoehlmacher J., Brabender J., Xiong Y.P., Uetake H., Danenberg K.D., Groshen S., Tsao-Wei D.D., Danenberg P.V., and Lenz H.J. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19 (2001) 4298-4304
19. Joshi M.B., Shirota Y., Danenberg K.D., Conlon D.H., Salonga D.S., Herndon II J.E., Danenberg P.V., and Harpole Jr. D.H. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 11 (2005) 2215-2221
20. Dabholkar M., Bostick-Bruton F., Weber C., Bohr V.A., Egwuagu C., and Reed E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84 (1992) 1512-1517
21. Dabholkar M., Vionnet J., Bostick-Bruton F., Yu J.J., and Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94 (1994) 703-708
22. Ozols R.F., Herbst R.S., Colson Y.L., Gralow J., Bonner J., Curran Jr. W.J., Eisenberg B.L., Ganz P.A., Kramer B.S., Kris M.G., Markman M., Mayer R.J., Raghavan D., Reaman G.H., Sawaya R., Schilsky R.L., Schuchter L.M., Sweetenham J.W., Vahdat L.T., and Winn R.J. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology. J Clin Oncol 25 (2007) 146-162
23. Bepler G., Gautam A., Simon G., Sharma S., Smith P., and Cantor A. PTEN, RRM1, and ERCC1 are coexpressed in non-small cell lung cancer (NSCLC) and are predictive of survival. Lung Cancer 41 Suppl. 2 (2003) 76
24. Rosell R., Felip E., Taron M., Majo J., Mendez P., Sanchez-Ronco M., Queralt C., Sanchez J.J., and Maestre J. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res 10 (2004) 4215s-4219s
25. Zheng Z., Chen T., Li X., Haura E., Sharma A., and Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356 (2007) 800-808
26. Kondo K, Fujino H, Takizawa H, Miyoshi T, Hirose Y, Nagao T, Nakagawa Y, Toba H, Yoshida M, Kenzaki K, Sakiyama S, Tangoku A. ERCC1 expression is one of prognostic factors in completely resected non-small cell lung cancer patients with an adjuvant platinum-based chemotherapy. J Thorac Oncol. 12th World conference on lung cancer, Seoul, Korea, September 2-6, 2007. 2(8) Supplement 4:S646, August 2007.
27. Olaussen K.A., Dunant A., Fouret P., Brambilla E., Andre F., Haddad V., Taranchon E., Filipits M., Pirker R., Popper H.H., Stahel R., Sabatier L., Pignon J.P., Tursz T., Le Chevalier T., and Soria J.C. DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355 (2006) 983-991
28. Lee KH, Min HS, Lee SH, Kim DW, Chung DH, Kim YT, Heo DS, Kim JH, Sung SW. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. J Thorac Oncol. 12th World conference on lung cancer, Seoul, Korea, September 2-6, 2007. 2(8) Supplement 4:S522, August 2007.
29. Arriagada R., Bergman B., Dunant A., Le Chevalier T., Pignon J.P., and Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 350 (2004) 351-360
30. Azuma K., Komohara Y., Sasada T., Terazaki Y., Ikeda J., Hoshino T., Itoh K., Yamada A., and Aizawa H. Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci 98 (2007) 1336-1343
31. Hwang I.G., Ahn M.J., Park B.B., Park S., Lee S.C., Ahn Y.C., Kim K., Kim J., Han J.H., Park K., Choi Y.S., Shim Y.M., and Ahn J.S. ERCC1 expression as a predictive marker in stage IIIA, N2 positive non-small lung cancer patients treated with neoadjuvant concurrent chemoradiotherapy followed by surgery. J Thorac Oncol 2 S4 (2007) S367
32. Wakelee H., Dubey S., and Gandara D. Optimal adjuvant therapy for non-small cell lung cancer-how to handle stage I disease. Oncologist 12 (2007) 331-337
33. Burdett S, Stewart LA, Rydzewska L. Chemotherapy and surgery versus surgery alone in non-small cell lung cancer. Cochrane Database Syst Rev 2007:CD006157.
34. Stewart LA, Burdett S, Tierney JF, Pignon JP, on behalf of the NSCLC Collaborative group. Surgery and adjuvant chemotherapy (CT) compared to surgery alone in non-small lung cancer (NSCLC): a meta-analysis using individual patient data (IPD) from randomized clinical trials (RCT). J Clin Oncol 2007 ASCO Annual Meeting Proceedings 25:7552.
35. Douillard J.Y., Rosell R., De Lena M., Carpagnano F., Ramlau R., Gonzales-Larriba J.L., Grodzki T., Pereira J.R., Le Groumellec A., Lorusso V., Clary C., Torres A.J., Dahabreh J., Souquet P.J., Astudillo J., Fournel P., Artal-Cortes A., Jassem J., Koubkova L., His P., Riggi M., and Hurteloup P. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7 (2006) 719-727
36. Winton T., Livingston R., Johnson D., Rigas J., Johnston M., Butts C., Cormier Y., Goss G., Inculet R., Vallieres E., Fry W., Bethune D., Ayoub J., Ding K., Seymour L., Graham B., Tsao M.S., Gandara D., Kesler K., Demmy T., and Shepherd F. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352 (2005) 2589-2597
37. Taillade L., Penault-Llorca F., Boulet T., Fouret P., Michiels S., Taranchon E., Mountzios G., Validire P., Domont J., Girard P., Grunenwald D., Le Chevalier T., and Soria J.C. Immunohistochemical expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small cell lung cancer. Ann Oncol 18 (2007) 1043-1050
38. Warnecke-Eberz U., Metzger R., Miyazono F., Baldus S.E., Neiss S., Brabender J., Schaefer H., Doerfler W., Bollschweiler E., Dienes H.P., Mueller R.P., Danenberg P.V., Hoelscher A.H., and Schneider P.M. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res 10 (2004) 3794-3799
39. Taron M., Rosell R., Felip E., Mendez P., Souglakos J., Ronco M.S., Queralt C., Majo J., Sanchez J.M., Sanchez J.J., and Maestre J. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 13 (2004) 2443-2449
40. de las Penas R., Sanchez-Ronco M., Alberola V., Taron M., Camps C., Garcia-Carbonero R., Massuti B., Queralt C., Botia M., Garcia-Gomez R., Isla D., Cobo M., Santarpia M., Cecere F., Mendez P., Sanchez J.J., and Rosell R. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small cell lung cancer patients. Ann Oncol 17 (2006) 668-675
41. Bepler G., Kusmartseva I., Sharma S., Gautam A., Cantor A., Sharma A., and Simon G. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small cell lung cancer. J Clin Oncol 24 (2006) 4731-4737
42. Potti A., Mukherjee S., Petersen R., Dressman H.K., Bild A., Koontz J., Kratzke R., Watson M.A., Kelley M., Ginsburg G.S., West M., Harpole Jr. D.H., and Nevins J.R. A genomic strategy to refine prognosis in early-stage non-small cell lung cancer. N Engl J Med 355 (2006) 570-580